Status:

RECRUITING

Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study

Lead Sponsor:

iOMEDICO AG

Collaborating Sponsors:

Servier Deutschland GmbH

Conditions:

Cholangiocarcinoma

Eligibility:

All Genders

18+ years

Brief Summary

Cholangiocarcinoma is a rare and aggressive tumor of the bile duct associated with a poor prognosis and very limited treatment options. The IDH1 inhibitor ivosidenib provides a new, targeted treatment...

Eligibility Criteria

Inclusion

  • Age 18 years or older.
  • Histologically confirmed locally advanced or metastatic CCC with a documented IDH1 R132 mutation diagnosed by an appropriate diagnostic test
  • Patients must have at least one prior systemic therapy
  • Decision for treatment with ivosidenib according to current SmPC.
  • Signed written informed consent before or within 6 weeks of first ivosidenib dose (inclusion of patients up to 6 weeks after first ivosidenib intake is allowed for patients not participating in the PRO module)
  • For patients participating in the PRO module (optional):
  • Dated signature of informed consent form before start of study treatment.
  • Willingness and capability to participate in PRO assessment in German language.
  • Other criteria according to current SmPC.

Exclusion

  • Participation in an interventional clinical trial within 30 days prior to enrolment or concurrent participation in an interventional clinical trial except for the follow-up period.
  • Other contraindications according to current SmPC.

Key Trial Info

Start Date :

October 8 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT06607302

Start Date

October 8 2024

End Date

December 1 2027

Last Update

November 26 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Hämatologisch-Onkologische Schwerpunktpraxis in Bad Liebenwerda

Bad Liebenwerda, Germany

2

Caritas Krankenhaus Bad Mergentheim

Bad Mergentheim, Germany

3

Onkologisches Versorgungszentrum Berlin MVZ

Berlin, Germany

4

Onkologie Hannover

Hanover, Germany

Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study | DecenTrialz